(Q33653612)

28 July 2017

1 reference

title

Secondary hormonal manipulations in hormone refractory prostate cancer (English)

1 reference

28 July 2017

1 reference

Reese DM

1

1 reference

28 July 2017

Small EJ

series ordinal

2

1 reference

28 July 2017

publication date

1 May 1999

1 reference

Urologic Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

26

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

311-21, viii

1 reference

Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Adrenalectomy and hypophysectomy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Phase II study of megestrol acetate for metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Antiandrogen withdrawal syndrome with nilutamide

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Ketoconazole therapy for hormonally refractive metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Megestrol acetate in the treatment of hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Clinical trials in relapsed prostate cancer: defining the target

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Response to orchiectomy following zoladentherapy for metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970071-9

7 January 2021

10.1016/S0094-0143(05)70071-9

Identifiers

DOI

1 reference

release_pnj2ba6xvbccfn22qznkuk5nti

28 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pnj2ba6xvbccfn22qznkuk5nti

24 November 2022

mapped directly with Wikidata item

1 reference